Key facts
- This page summarizes Robert J. Bitterman's Form 4 filing for Phio Pharmaceuticals Corp. (PHIO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 29 Jun 2026, 16:02.
Robert J. Bitterman - 26 Jun 2026 Form 4 Insider Report for Phio Pharmaceuticals Corp. (PHIO)
- Reporting relationship
- Chairman, Pres. & CEO, Director
- Issuer ticker
- PHIO
- Reported as of
- 26 Jun 2026
- Net transaction value
- +$9,900
- SEC form
- 4
- Accepted by SEC
- 29 Jun 2026, 16:02:13 UTC
- Prior SEC filing
- 06 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lisa C. Carson, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Robert J. Bitterman filed Form 4 for Phio Pharmaceuticals Corp. (PHIO) on 29 Jun 2026.
Change
- Previous filing in this sequence was filed on 06 Feb 2026.
- Current net transaction value: +$9,900.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001304395
Primary reporting owner
Bitterman Robert J
- Relationship
- Chairman, Pres. & CEO, Director
- Address
- C/O PHIO PHARMACEUTICALS CORP., 411 SWEDELAND RD., STE 23-1080, KING OF PRUSSIA
- Signature
- /s/ Lisa C. Carson, Attorney-in-fact
- Signature date
- 29 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PHIO
transaction
Common Stock, $.0001 par value
Purchase
- Transaction value
- $9,900
- Shares
- +10,000
- Change %
- +2.4%
- Price
- $0.9900
- Shares after
- 421,421
- Date
- 26 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Includes shares of common stock underlying unvested restricted stock units.